PERCFPercheron Therapeutics Ltd

About Percheron Therapeutics Ltd (PERCF)

Percheron Therapeutics Ltd (PERCF) is a Drug Manufacturers - Specialty & Generic company headquartered in Melbourne, VA, Australia whose shares trade over-the-counter on the Pink tier.

Percheron Therapeutics Limited is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy.

Products and services

The company engages in the research and development of novel antisense pharmaceuticals.

PERCF key facts

Ticker symbol

PERCF

Market tier

Pink

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Melbourne, VA, Australia

Country of incorporation

AU

Year of incorporation

2000

Employees

4

Estimated market cap

$4.35M (as of May 13, 2025)

Shares outstanding

1,087,437,633

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Quarterly Report (Mar 31, 2025)

Percheron Therapeutics Ltd leadership

• James Stuart Garner — CEO, Managing Director
• Deborah Leonie Ambrosini — CFO, Company Secretary
• Susan Turner — Controller
• David Batista — Other

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · Pink stocks · OTC stocks starting with P